Stem cell derived cardiomyocytes gain more and more attention in the field of cardiovascular research, disease modeling and drug development.
The CERO 3D Incubator & Bioreactor streamlines the process, enabling stem cell expansion into uniform aggregates followed by direct induction into a high yield of beating cardiac bodies. Compared to traditional orbital shakers, CERO 3D offers superior cell quality, homogeneity, integrity, and yield in both pluripotent stem cell expansion and cardiac differentiation.
CERO 3D Incubator & Bioreactor versus Orbital Shaker
Differentiation of murine embryonic stem cell-derived cardiomyocytes at days 3, 8, and 13 post-induction (from top to bottom).
Purified and homogeneous cardiac bodies generated in CERO 3D Incubator & Bioreactor are a perfect tools for disease modeling and drug discovery. The pure cardiomyocytes can also be used in 2D downstream monolayer applications.
Homogeneous 3D aggregates in suspension
Expansion and differentiation in the same CEROtube
Easy to handle & standardize
Highest yield, no substrate required
Greater relevance for drug testing and disease modeling
The overarching aim of all our studies is the identification and development of clinically relevant therapeutic agents for the treatment of human heart disease. To that end we utilize human self-organised cardiac organoids for high throughput drug screening and in vivo genetic models of human congenital disease, as our experimental platform, in combination with adeno-associated virus (AAV) and anti-sense RNAs as therapeutic agents. The CERO 3D has considerably simplified our cardiac organoid generation workflow and enabled us to scale-up organoid production signficantly. Organoids generated with CER 3D reveal improved cellular organisation, and display uniformity and consistency within and across production batches.
Moreover this 3D cultivation system substantially improves viability, maturation and contractility, therefore provides a reliable tool for cardiovascular therapies
